Vistagen secures patent for non-opioid pain treatment
SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...
Nature1 年
New paths to pain relief
Existing opioid agents that trigger central as well ... In turn, GluRs can be divided into three subtypes: N-methyl-d-aspartate (NMDA) receptors, kainate receptors, and AMPA ((2-aminomethyl ...
FDA approves first new non-opioid pain pill in decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
Vistagen granted USPTO patent for AV-101 to treat neuropathic pain
Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...
来自MSN1 天
USPTO grants patent to Vistagen’s neuropathic pain treatment
The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for neuropathic pain treatment. This patent is set to remain in effect until at ...
Palm Beach Post6 天
FDA approves new pain medicine as opioid alternative. What to know about Journavx
For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug ...
Medical Xpress11 天
A high-resolution 'map' reveals the structural and functional complexity of endogenous NMDA ...
NMDA receptors, members of the excitatory ionotropic glutamate receptor family, are essential to these processes. They regulate the strength of synaptic connections, playing a critical role in ...